Multifunctional antioxidant nanoliposome‐mediated delivery of PTEN plasmids restore the expression of tumor suppressor protein and induce apoptosis in prostate cancer cells
Source abstract
Abstract
Abstract Prostate cancer is the second leading cause of cancer death in men and about one in nine will be diagnosed in his lifetime. Loss of PTEN has been considered as one of the major factors leading to the origin of prostate cancer through modulating PI3K/AKT signaling pathways. In this study, we have prepared a multifunctional antioxidant nanoliposome containing PTEN plasmid and cerium oxide nanoparticles (CeNPs). The efficient delivery of PTEN plasmid to human prostate cancer cells (PC‐3) leads to restoration of the expression of lost PTEN protein in the cell cytoplasm. The delivered superoxide dismutase (SOD)‐mimetic CeNPs were also found to decrease the cytoplasmic free radical levels in prostate cancer cells. The above two activities induced DNA fragmentation and micronucleus formation in prostate cancer cells. Furthermore, it was also found that these multifunctional antioxidant nanoliposomes inhibit the PI3K/AKT signaling pathway to negatively regulate the cell viability of prostate cancer cells. The mRNA expression pattern of other relevant proteins predominantly involved in cancer cell proliferation and apoptosis suggested that the high PTEN expression could control the synthesis of oncogenic proteins. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 3152–3164, 2018.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Biological and Life Science School of Arts and Science, Ahmedabad University Ahmedabad 380009 Gujarat India
Funding
Science and Engineering Research Board
References (59)
Show source-provided references
1. 10.1016/j.eururo.2016.05.04310.1016/j.eururo.2016.05.043 ↗
2. 10.1016/j.cell.2008.04.01310.1016/j.cell.2008.04.013 ↗
3. 10.2174/15680090878429365910.2174/156800908784293659 ↗
4. 10.1093/carcin/bgm05210.1093/carcin/bgm052 ↗
5. 10.1042/BJ2008161010.1042/BJ20081610 ↗
6. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells
7. 10.1073/pnas.95.16.941810.1073/pnas.95.16.9418 ↗
8. 10.1016/S0092-8674(00)80674-110.1016/S0092-8674(00)80674-1 ↗
9. 10.1074/jbc.M60539120010.1074/jbc.M605391200 ↗
10. Clinical development of liposome‐based drugs: Formulation, characterization, and therapeutic efficacy
11. Nanomaterials as non‐viral sirna delivery agents for cancer therapy
12. 10.1021/acsnano.7b0208210.1021/acsnano.7b02082 ↗
13. 10.2147/IJN.S12470110.2147/IJN.S124701 ↗
14. 10.1158/1535-7163.MCT-16-028510.1158/1535-7163.MCT-16-0285 ↗
15. Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer
16. 10.1023/A:101103780726110.1023/A:1011037807261 ↗
17. 10.4081/vl.2018.719610.4081/vl.2018.7196 ↗
18. 10.1158/0008-5472.CAN-12-152710.1158/0008-5472.CAN-12-1527 ↗
19. 10.1016/j.cis.2014.11.00410.1016/j.cis.2014.11.004 ↗
20. 10.2174/138920021666615062512154610.2174/1389200216666150625121546 ↗
21. 10.2174/138920101566614050812255810.2174/1389201015666140508122558 ↗
22. 10.2174/138161282299916012212171310.2174/1381612822999160122121713 ↗
23. 10.2174/138161282266615121012354610.2174/1381612822666151210123546 ↗
24. 10.2147/IJN.S12470710.2147/IJN.S124707 ↗
25. 10.1002/jbm.a.3626810.1002/jbm.a.36268 ↗
26. 10.1016/j.bioactmat.2017.09.00610.1016/j.bioactmat.2017.09.006 ↗
27. 10.18632/oncoscience.1210.18632/oncoscience.12 ↗
28. 10.1016/j.canlet.2015.03.00710.1016/j.canlet.2015.03.007 ↗
29. 10.1093/carcin/bgq10510.1093/carcin/bgq105 ↗
30. 10.1016/j.actbio.2018.02.02210.1016/j.actbio.2018.02.022 ↗
31. 10.1038/s41419-018-0379-210.1038/s41419-018-0379-2 ↗
32. 10.2174/15680090778322040810.2174/156800907783220408 ↗
33. 10.1002/ijc.2254810.1002/ijc.22548 ↗
34. 10.1158/0008-5472.CAN-06-214710.1158/0008-5472.CAN-06-2147 ↗
35. 10.1097/JTO.0b013e31821034ae10.1097/JTO.0b013e31821034ae ↗
36. Catalytically active nanomaterials: Artificial enzymes of next generation
37. 10.1016/j.colsurfb.2015.05.00510.1016/j.colsurfb.2015.05.005 ↗
38. 10.1039/b615134e10.1039/b615134e ↗
39. 10.1039/b922024k10.1039/b922024k ↗
40. 10.1016/j.biomaterials.2011.05.07310.1016/j.biomaterials.2011.05.073 ↗
41. 10.1039/c2nr12131j10.1039/c2nr12131j ↗
42. 10.1002/cyto.99005010510.1002/cyto.990050105 ↗
43. 10.1080/1071754049028070510.1080/10717540490280705 ↗
44. 10.1021/mp400470p10.1021/mp400470p ↗
45. 10.1016/j.ymthe.2004.02.00910.1016/j.ymthe.2004.02.009 ↗
46. 10.1038/srep2587910.1038/srep25879 ↗
47. 10.1155/2016/247684210.1155/2016/2476842 ↗
48. 10.1155/2016/431320410.1155/2016/4313204 ↗
49. 10.1242/jcs.114.16.290310.1242/jcs.114.16.2903 ↗
50. 10.1111/j.1749-6632.2012.06750.x10.1111/j.1749-6632.2012.06750.x ↗
51. 10.1038/nrm333010.1038/nrm3330 ↗
52. 10.3109/09687688.2012.74517510.3109/09687688.2012.745175 ↗
53. 10.1016/j.biocel.2009.09.01310.1016/j.biocel.2009.09.013 ↗
54. 10.1073/pnas.96.8.424010.1073/pnas.96.8.4240 ↗
55. AKT‐1, −2, and −3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon
56. 10.1042/bj335000110.1042/bj3350001 ↗
57. 10.18632/oncotarget.455310.18632/oncotarget.4553 ↗
58. 10.1002/pros.2041010.1002/pros.20410 ↗
59. 10.1182/blood-2004-03-084910.1182/blood-2004-03-0849 ↗